Premature LabourEcho-colNCT02598323
Prevention and Treatment of Premature Labour for Asymptomatic Pregnant Women
A study testing ultrasound in people with Premature Labour, run by Assistance Publique Hopitaux De Marseille at 1 site in France.
Trial summary
State of the question and research objective: International trials have shown that ultrasound measurement of the cervix identifies a population at high risk of preterm delivery. In case of short neck several types of treatments can be recommended: progesterone, the establishment of a strapping or pessary. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Premature Labour
- What is being tested?
- ultrasound
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,500 participants
- Where
- 1 siteFrance
- Study dates
- Nov 2015to Nov 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age> 18 years,
- pregnancy with single fetus,
- gestational age between 16SA and 26SA,
- asymptomatic patients, that is to say, without sign of preterm labor layout
Who cannot join
- Maternal Pathology (Pre Eclampsia, non-insulin dependent diabetes, insulin dependent gestational diabetes or unbalanced)
- uterine malformation
- fetal malformation or fetal chromosomal abnormality
- premature Work in Progress (cervix dilated to more than 2 cm or regular uterine contractions and felt)
- Signs of chorioamnionitis
- Allergy to progesterone
- Taking progesterone in the month preceding the inclusion
Trial locations and contacts
1 site in 1 country.
Cecile CHAU, MD contact
About this study
Official title: Premature Labour Screening by Cervical Ultrasound for Asymptomatic Pregnant Women in the PACA Region. Various Treatment Strategies : 1. Progesterone 200mg (Vaginal Way) 2. Pessary 3. Vaginal Stitching 4. Rest
State of the question and research objective: International trials have shown that ultrasound measurement of the cervix identifies a population at high risk of preterm delivery. In case of short neck several types of treatments can be recommended: progesterone, the establishment of a strapping or pessary. These three treatments reduce the risk of preterm delivery. There is no French study.
The objective of this study is to reduce prematurity in the PACA region Monaco-Corsica by introducing a routine ultrasound screening strategy asymptomatic short necks.
Read more
Population concerned: All patients with active singleton pregnancy between 16 and 26 SA SA are eligible to ultrasound of the cervix.
- Primary endpoint: delivery rate before 37 weeks.
- Criteria secondary judgments rate of deliveries before 37 weeks, neonatal mortality morbidity.
Expected result: a prematurity of 50%
Read the detailed description
State of the question and research objective: International trials have shown that ultrasound measurement of the cervix identifies a population at high risk of preterm delivery. In case of short neck several types of treatments can be recommended: progesterone, the establishment of a strapping or pessary. These three treatments reduce the risk of preterm delivery. There is no French study.
The objective of this study is to reduce prematurity in the PACA region Monaco-Corsica by introducing a routine ultrasound screening strategy asymptomatic short necks.
Expected result: a prematurity of 50%
Population concerned: All patients with active singleton pregnancy between 16 and 26 SA SA are eligible to ultrasound of the cervix.
Method of observation and deduction investigation: Study before / after comparing two periods: period A (2013) and Period B (2015).
- Primary endpoint: delivery rate before 37 weeks.
- Criteria secondary judgments rate of deliveries before 37 weeks, neonatal mortality morbidity.
Data flow mode:
Duration and terms of organization of research: The actual duration of the study (preparation and implementation, monitoring and inclusions) is set at 36 months. This study will be conducted in the context of networks. All maternity hospitals belonging to these networks will be invited to participate. Referents investigating doctors will be appointed.
The attaché of clinical research in collaboration with the Network Coordinator, Michele Marcot, get back the data for the year 2013 by the transfer records examination, delivery specifications, reviews of the hospitalization mother and child.
Data collection for 2015 will be based on a collection form that will complement the investigators involved in the project at the inclusion of the patient.
These sheets will be collected in real time by the RCAF in charge of monitoring the study will proceed to their seizure.
Positive cases (short necks - less than 25mm) will be offered or not progesterone treatment, banding or the establishment of a pessary according to the habits of the practitioner and the service protocol.
If treatment with progesterone is retained, it is Vaginal Progesterone 200mg, natural micronized progesterone without excipients with known effect in capsule form.
Data Analysis Method: Statistical analysis will be initiated only after verification of the validity of the database (queries broadcast from clinicians involved in the study, consistency checks). There is a procedure and data anonymization algorithm giving each individual a number. A lookup table is available, separate from the operating base. Only the number will be entered into the computer database. The database will then be frozen. After the base gel, the consolidated data will be processed by the statistician. Data analysis will be performed using the SPSS Version 17.0 software for Windows by the statistician of the Unit for Clinical Research Methodology (Loundou Anderson, head Prof. Pascal Auquier).
Statistical significance tests will be set at 5%. The type of unilateral or bilateral test will depend on the chosen alternative, especially based on the results already available in previous studies.
The qualitative variables are expressed in terms of numbers and percentages, and quantitative variables will be reported using the usual parameters of position (mean, median) and dispersion (standard deviation, range). The normality of the distributions of quantitative data will be systematically searched using the Shapiro-Wilks test. If variables are not normally distributed, conventional processing techniques (logarithmic, ...) will be implemented.
Initially, a comparability study populations for inclusion will be made on all the variables collected at that time: socio-demographic and clinical (using Mantel-Haenszel test, the Chi-2 or accurate Fisher for qualitative variables, and Student's t test or ANOVA for quantitative variables) to reveal potential confounding factors to consider when analyzing the criteria of judgment. Comparisons between the study populations will also be conducted on all the criteria of secondary judgments. Adjustments will be made on the variables identified as confounding factors by conducting multivariate analysis (analysis of variance, multivariate logistic regression).
Justification of the number of subjects or power analysis: The prematurity rate was 7.4% in 2013 in France (PACA, Périnat data 2010).
We expect a reduction in this rate of 1.5 points (or 6%) over the period 2015 referring to the reduction of prematurity obtained by Kiss, et al, 2003.
To achieve this reduction in preterm birth rate, include 3500 patients in each period. Considering the selection criteria and the active files of the various partners, the inclusion of patients in the period 3500 2014 is quite achievable.
(44,000 births per year at the network level, among which are ensuring that 10% of them meet the predefined criteria). Regarding the second period, the reasoning is the same; among the list of eligible patients, a random draw will be conducted to determine the 3500 patients representing this period. Thus for 3500 patients included in the period 2014, 10% will have a short neck or 350 patients who will be offered the Progesterone, a banding or the establishment of a pessary.
- Conditions
- Premature Labour
- Being tested
- ultrasound
- Medical subject headings
- Obstetric Labor, Premature
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ultrasoundDevice
| Study group | Role | What they receive |
|---|---|---|
| patients with active singleton pregnancy between 16 and 26 SA | Experimental | Not described Receives: Device: ultrasound |
What is being measured
The primary outcome is the main question the study is designed to answer.
delivery rate before 37 weeks
Measured: 21 weeks maximum
Secondary outcomes (3)
neonatal mortality
Measured: about 30 weeks
rate of newborns admitted to intensive care in the first month of life
Measured: about 30 weeks
length of stay in intensive care
Measured: about 30 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2015 (estimated)
- Study startNov 2015
- Primary completionNov 2017 (estimated)
- Study completionNov 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Premature LabourStudies of the same condition, open and under way.
- More trials run by Assistance Publique Hopitaux De MarseilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 3,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Urielle Desalbres, Study director, AP-HM
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02598323
- Sponsor's protocol ID
- 2014-24
- Other IDs
- AP-HM
- Acronym
- Echo-col
- Status last verified
- Nov 2015
- First submitted
- 4 Nov 2015
- Last updated
- 5 Nov 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Figarella A, Chau C, Loundou A, d'Ercole C, Bretelle F. The introduction of a universal transvaginal cervical length screening program is associated with a reduced preterm birth rate. Am J Obstet Gynecol. 2023 Feb;228(2):219.e1-219.e14. doi: 10.1016/j.ajog.2022.07.046. Epub 2022 Aug 4.
PubMed 35932876
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Premature Labour Screening by Cervical Ultrasound for Asymptomatic Pregnant Women in the PACA Region. Various Treatment Strategies : 1. Progesterone 200mg (Vaginal Way) 2. Pessary 3. Vaginal Stitching 4. Rest
- ClinicalTrials.gov ID
- NCT02598323
- Acronym / sponsor ID
- Echo-col / 2014-24
- Conditions
- Premature Labour
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 3,500 participants (estimated)
- Lead sponsor
- Assistance Publique Hopitaux De MarseilleUniversity, hospital or other
- Study start
- Nov 2015
- Primary completion
- Nov 2017 (estimated)
- Study completion
- Nov 2018 (estimated)
- First posted
- 5 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
State of the question and research objective: International trials have shown that ultrasound measurement of the cervix identifies a population at high risk of preterm delivery. In case of short neck several types of treatments can be recommended: progesterone, the establishment of a strapping or pessary. These three treatments reduce the risk of preterm delivery. There is no French study.
The objective of this study is to reduce prematurity in the PACA region Monaco-Corsica by introducing a routine ultrasound screening strategy asymptomatic short necks.
Population concerned: All patients with active singleton pregnancy between 16 and 26 SA SA are eligible to ultrasound of the cervix.
- Primary endpoint: delivery rate before 37 weeks.
- Criteria secondary judgments rate of deliveries before 37 weeks, neonatal mortality morbidity.
Expected result: a prematurity of 50%
Detailed description
State of the question and research objective: International trials have shown that ultrasound measurement of the cervix identifies a population at high risk of preterm delivery. In case of short neck several types of treatments can be recommended: progesterone, the establishment of a strapping or pessary. These three treatments reduce the risk of preterm delivery. There is no French study.
The objective of this study is to reduce prematurity in the PACA region Monaco-Corsica by introducing a routine ultrasound screening strategy asymptomatic short necks.
Expected result: a prematurity of 50%
Population concerned: All patients with active singleton pregnancy between 16 and 26 SA SA are eligible to ultrasound of the cervix.
Method of observation and deduction investigation: Study before / after comparing two periods: period A (2013) and Period B (2015).
- Primary endpoint: delivery rate before 37 weeks.
- Criteria secondary judgments rate of deliveries before 37 weeks, neonatal mortality morbidity.
Data flow mode:
Duration and terms of organization of research: The actual duration of the study (preparation and implementation, monitoring and inclusions) is set at 36 months. This study will be conducted in the context of networks. All maternity hospitals belonging to these networks will be invited to participate. Referents investigating doctors will be appointed.
The attaché of clinical research in collaboration with the Network Coordinator, Michele Marcot, get back the data for the year 2013 by the transfer records examination, delivery specifications, reviews of the hospitalization mother and child.
Data collection for 2015 will be based on a collection form that will complement the investigators involved in the project at the inclusion of the patient.
These sheets will be collected in real time by the RCAF in charge of monitoring the study will proceed to their seizure.
Positive cases (short necks - less than 25mm) will be offered or not progesterone treatment, banding or the establishment of a pessary according to the habits of the practitioner and the service protocol.
If treatment with progesterone is retained, it is Vaginal Progesterone 200mg, natural micronized progesterone without excipients with known effect in capsule form.
Data Analysis Method: Statistical analysis will be initiated only after verification of the validity of the database (queries broadcast from clinicians involved in the study, consistency checks). There is a procedure and data anonymization algorithm giving each individual a number. A lookup table is available, separate from the operating base. Only the number will be entered into the computer database. The database will then be frozen. After the base gel, the consolidated data will be processed by the statistician. Data analysis will be performed using the SPSS Version 17.0 software for Windows by the statistician of the Unit for Clinical Research Methodology (Loundou Anderson, head Prof. Pascal Auquier).
Statistical significance tests will be set at 5%. The type of unilateral or bilateral test will depend on the chosen alternative, especially based on the results already available in previous studies.
The qualitative variables are expressed in terms of numbers and percentages, and quantitative variables will be reported using the usual parameters of position (mean, median) and dispersion (standard deviation, range). The normality of the distributions of quantitative data will be systematically searched using the Shapiro-Wilks test. If variables are not normally distributed, conventional processing techniques (logarithmic, ...) will be implemented.
Initially, a comparability study populations for inclusion will be made on all the variables collected at that time: socio-demographic and clinical (using Mantel-Haenszel test, the Chi-2 or accurate Fisher for qualitative variables, and Student's t test or ANOVA for quantitative variables) to reveal potential confounding factors to consider when analyzing the criteria of judgment. Comparisons between the study populations will also be conducted on all the criteria of secondary judgments. Adjustments will be made on the variables identified as confounding factors by conducting multivariate analysis (analysis of variance, multivariate logistic regression).
Justification of the number of subjects or power analysis: The prematurity rate was 7.4% in 2013 in France (PACA, Périnat data 2010).
We expect a reduction in this rate of 1.5 points (or 6%) over the period 2015 referring to the reduction of prematurity obtained by Kiss, et al, 2003.
To achieve this reduction in preterm birth rate, include 3500 patients in each period. Considering the selection criteria and the active files of the various partners, the inclusion of patients in the period 3500 2014 is quite achievable.
(44,000 births per year at the network level, among which are ensuring that 10% of them meet the predefined criteria). Regarding the second period, the reasoning is the same; among the list of eligible patients, a random draw will be conducted to determine the 3500 patients representing this period. Thus for 3500 patients included in the period 2014, 10% will have a short neck or 350 patients who will be offered the Progesterone, a banding or the establishment of a pessary.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients with active singleton pregnancy between 16 and 26 SA | Experimental | Device: ultrasound |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age> 18 years,
- pregnancy with single fetus,
- gestational age between 16SA and 26SA,
- asymptomatic patients, that is to say, without sign of preterm labor layout
Key exclusion criteria (7 listed)
- Maternal Pathology (Pre Eclampsia, non-insulin dependent diabetes, insulin dependent gestational diabetes or unbalanced)
- uterine malformation
- fetal malformation or fetal chromosomal abnormality
- premature Work in Progress (cervix dilated to more than 2 cm or regular uterine contractions and felt)
- Signs of chorioamnionitis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ultrasound | Device | patients with active singleton pregnancy between 16 and 26 SA |
Primary outcome
delivery rate before 37 weeks
Time frame: 21 weeks maximum
3 secondary outcomes
neonatal mortality
Time frame: about 30 weeks
rate of newborns admitted to intensive care in the first month of life
Time frame: about 30 weeks
length of stay in intensive care
Time frame: about 30 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2015.
- Derived from this study: PubMed 35932876Figarella A, Chau C, Loundou A, d'Ercole C, Bretelle F. The introduction of a universal transvaginal cervical length screening program is associated with a reduced preterm birth rate. Am J Obstet Gynecol. 2023 Feb;228(2):219.e1-219.e14. doi: 10.1016/j.ajog.2022.07.046. Epub 2022 Aug 4.
Related trials for Premature Labour
RecruitingObservational study
Cervical Stiffness in Women With Threatened Preterm Labor
Preterm Labor, Preterm Birth
Recruiting
Intravenous Papaverine for Term Prelabor Rupture of Membranes
Premature Rupture of Fetal Membranes
Recruiting
Maternal Stress on Human Milk and Infant Outcomes
Postpartum Depression, Preterm Labor
Active, not recruitingObservational study
Is the Vaginal Microbiome and Metabolome Associated With Spontaneous Preterm Birth (sPTB) in Multiple Pregnancies?
Preterm Birth, Preterm Labor
Active, not recruitingObservational study
IL-6 and Lactates in Cord Blood and Neonatal Outcomes
Fetal Infection, Fetal Inflammatory Response Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Cecile CHAU, MD contact
Urielle Desalbres study director
AP-HM
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ultrasound in people with Premature Labour, run by Assistance Publique Hopitaux De Marseille at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Cecile CHAU, MD (cecile.chau@ap-hm.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
delivery rate before 37 weeks (time frame: 21 weeks maximum). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02598323, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2015.